HLX CXCR4 C1013G Case

Synonyms
Allscripts (AEHR) Order Name	CXCR4 C1013G Mutation Analysis
Sunrise Clinical Manager (SCM) Order Name	CXCR4 C1013G Mutation Analysis
EPIC Order Name	CXCR4 C1013G Mutation Molecular Detection
Clinical Info	CXCR4 C1013G Mutation Analysis CXCR4 C1013G mutation has been described as the most frequent recurrent CXCR4 mutation identified in WM patients. Most of these cases with CXCR4 mutations have concurrent MYD88 L265P mutations. This patient may be eligible for treatment with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. CXCR4 mutations are associated with resistance to ibrutinib in patients with WM.
Specimen Type	Blood, Bone Marrow
Specimen Volume	1-3 mL Whole blood or Bone Marrow
Container	Lavender Top Tube
Collection Instructions	Container/Tube: Lavender Top Tube Specimen 1 - 3 mL Whole Blood or Bone Marrow
Transport Instructions	Room Temperature
Specimen Stability	Specimens are stable for a week refrigerated
Methodology	Allele Specific Real Time Polymerase Chain Reaction (RT-PCR)
Days Performed	Monday through Friday TAT: 8 Calendar days
Performing Laboratory	Northwell Health Laboratories
CPT	81479
PDM	248466
Result Interpretation Detected (mutation is present) Not detected (mutation is absent)
Forms	Molecular test Requisition Form Heme/Onc Requisition

Synonyms